Log in to search using one of your social media accounts:


Wilmot Discovery Improves Use of Umbilical Cord Blood as Cancer Therapy

A clinician/scientist, who studies ways to make cord-blood transplants for leukemia and lymphoma patients safer and more effective, recently reported a new finding in the journal, Blood. An accompanying editorial called the research “a breath of fresh air” for overcoming barriers to make this a viable option for many patients.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Source Type: news

Related Links:

According to 2010-2012 data from the National Cancer Institute (NCI), 40% of men and women will be diagnosed with cancer in their lifetime. In all its forms, cancer is known to be a clinically and emotionally challenging disease to manage. Despite th...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Exclusive Oncology Pathology Source Type: blogs
AbstractPurpose of ReviewIn this paper, we summarize prior studies that have used Mendelian randomization (MR) methods to study the effects of exposures, lifestyle factors, physical traits, and/or biomarkers on cancer risk in humans. Many such risk factors have been associated with cancer risk in observational studies, and the MR approach can be used to provide evidence as to whether these associations represent causal relationships. MR methods require a risk factor of interest to have known genetic determinants that can be used as proxies for the risk factor (i.e., “instrumental variables” or IVs), and these c...
Source: Current Epidemiology Reports - Category: Epidemiology Source Type: research
B-lymphoblastic leukemia/lymphoma (B-ALL) is an aggressive hematologic malignancy currently subcategorized into multiple genetic subtypes based on the identification of recurrent acquired chromosome abnormalities. Identification and accurate characterization of these multiple and varied chromosome abnormalities is essential to the diagnosis, prognosis and emerging predictive therapeutic targets in B-ALL patients and is typically achieved through standard karyotyping and fluorescence in situ hybridization (FISH) testing.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conclusions: Although administrative data alone did not validly identify cancer-related events, administrative data in combination with chart collected EOIT dates was associated with excellent validity. The collection of EOIT dates by cancer registries would significantly expand the potential of administrative data linkage to assess cancer outcomes.
Source: Medical Care - Category: Health Management Tags: Online Article: Applied Methods Source Type: research
Authors: He W, Hu H Abstract Heat shock proteins (HSPs) are molecular chaperones that are consistently increased to help cells survive under conditions of stress. As a member of the Hsps, Hsp90 is involved in protein post‑translational maturation and disposition. This protein is ubiquitously expressed in normal cells. However, in cancer cells and particularly in hematological malignancies, Hsp90 is unexpectedly abundant to maintain levels of proteins vital for cancer pathology. Hsp90 inhibitors can target the ATP domain of Hsp90 and prohibit its exchange of ADP for ATP, leading to the degradation of client protei...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
WEDNESDAY, May 9, 2018 -- Survivors of lymphoma and chronic lymphocytic leukemia (CLL) have increased use of health care services versus a normative population, according to a study published online April 26 in Cancer. Lindy P.J. Arts, from the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Authors: Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJS, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O Abstract Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic protein...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
HTLV-1, which can cause leukemia and lymphoma, has infected more than 40 per cent of adults in isolated communities in central Australia, with indigenous people being the worst hit.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
HTLV-1, which can cause leukemia and lymphoma, has infected more than 40 per cent of adults in isolated communities in central Australia, with indigenous people being the worst hit.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Leukemia | Lymphoma | Study | Transplants | Universities & Medical Training